Baidu
map

转化医学

订阅

MedSci主页 / 所有栏目 / 转化医学

谷峰：PAM序列可影响CRISPR/Cas9介导的基因组编辑效率

2014-09-29 佚名 生物谷

基因修复机制
关注

9月26日，由生物谷主办的2014基因组编辑研讨会在上海好望角大饭店隆重举行。温州医科大学附属眼视光医院的谷峰教授参加了此次大会并发表了题为"PAM序列对CRISPR/Cas9介导的基因组编辑的影响及AAV-CRISPR/Cas9对人类胚胎干细胞的基因组编辑"的精彩报告。 谷教授基于GFP报告系统，通过定性和定量的方法，系统的研究了PAM序列对CRISPR/Cas9介导的基因组编辑的影响。他

9月26日，由生物谷主办的2014基因组编辑研讨会在上海好望角大饭店隆重举行。温州医科大学附属眼视光医院的谷峰教授参加了此次大会并发表了题为"PAM序列对CRISPR/Cas9介导的基因组编辑的影响及AAV-CRISPR/Cas9对人类胚胎干细胞的基因组编辑"的精彩报告。

谷教授基于GFP报告系统，通过定性和定量的方法，系统的研究了PAM序列对CRISPR/Cas9介导的基因组编辑的影响。他们除了验证了之前张峰教授发表在《自然生物技术》上的NGG的效率高于NAG之外，还系统的比较了NGA这种PAM结构与其他两种PAM结构对基因组编辑效率的影响。结果显示，这三种PAM结构均有介导Cas9切割基因组的能力，并且其介导切割效率依次为：NGG>NGA>NAG.

另外，谷峰教授还讲述了他们利用AAV-CRISPR/Cas9对人类胚胎干细胞的基因组进行的定点编辑的相关工作，他们将RFP基因成功插入到视网膜光感受器特意表达的基因NRL位点，这种基因敲除的的胚胎干细胞对干细胞介导的人类视网膜疾病的治疗具有重要意义。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=36769, encodeId=f77936e69cd, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36770, encodeId=11b036e70c6, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36766, encodeId=110c36e6624, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36767, encodeId=4d4c36e6701, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36768, encodeId=dbc036e6858, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950091, encodeId=807e1950091bb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Mon Oct 27 19:28:00 CST 2014, time=2014-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275814, encodeId=82be12e5814bc, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341217, encodeId=37c6134121ec4, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364975, encodeId=c5ba13649e5f8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585947, encodeId=f1f7158594e2e, content=<a href='/topic/show?id=7ed041850a1' target=_blank style='color:#2F92EE;'>#基因组编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41850, encryptionId=7ed041850a1, topicName=基因组编辑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=)]
    2015-09-10 he408015781

    期待进一步的研究

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=36769, encodeId=f77936e69cd, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36770, encodeId=11b036e70c6, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36766, encodeId=110c36e6624, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36767, encodeId=4d4c36e6701, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36768, encodeId=dbc036e6858, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950091, encodeId=807e1950091bb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Mon Oct 27 19:28:00 CST 2014, time=2014-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275814, encodeId=82be12e5814bc, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341217, encodeId=37c6134121ec4, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364975, encodeId=c5ba13649e5f8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585947, encodeId=f1f7158594e2e, content=<a href='/topic/show?id=7ed041850a1' target=_blank style='color:#2F92EE;'>#基因组编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41850, encryptionId=7ed041850a1, topicName=基因组编辑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=)]
    2015-09-10 he408015781

    期待进一步的研究

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=36769, encodeId=f77936e69cd, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36770, encodeId=11b036e70c6, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36766, encodeId=110c36e6624, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36767, encodeId=4d4c36e6701, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36768, encodeId=dbc036e6858, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950091, encodeId=807e1950091bb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Mon Oct 27 19:28:00 CST 2014, time=2014-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275814, encodeId=82be12e5814bc, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341217, encodeId=37c6134121ec4, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364975, encodeId=c5ba13649e5f8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585947, encodeId=f1f7158594e2e, content=<a href='/topic/show?id=7ed041850a1' target=_blank style='color:#2F92EE;'>#基因组编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41850, encryptionId=7ed041850a1, topicName=基因组编辑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=)]
    2015-09-10 he408015781

    期待进一步的研究

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=36769, encodeId=f77936e69cd, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36770, encodeId=11b036e70c6, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36766, encodeId=110c36e6624, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36767, encodeId=4d4c36e6701, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36768, encodeId=dbc036e6858, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950091, encodeId=807e1950091bb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Mon Oct 27 19:28:00 CST 2014, time=2014-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275814, encodeId=82be12e5814bc, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341217, encodeId=37c6134121ec4, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364975, encodeId=c5ba13649e5f8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585947, encodeId=f1f7158594e2e, content=<a href='/topic/show?id=7ed041850a1' target=_blank style='color:#2F92EE;'>#基因组编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41850, encryptionId=7ed041850a1, topicName=基因组编辑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=)]
    2015-09-10 he408015781

    期待进一步的研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=36769, encodeId=f77936e69cd, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36770, encodeId=11b036e70c6, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36766, encodeId=110c36e6624, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36767, encodeId=4d4c36e6701, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36768, encodeId=dbc036e6858, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950091, encodeId=807e1950091bb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Mon Oct 27 19:28:00 CST 2014, time=2014-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275814, encodeId=82be12e5814bc, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341217, encodeId=37c6134121ec4, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364975, encodeId=c5ba13649e5f8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585947, encodeId=f1f7158594e2e, content=<a href='/topic/show?id=7ed041850a1' target=_blank style='color:#2F92EE;'>#基因组编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41850, encryptionId=7ed041850a1, topicName=基因组编辑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=)]
    2015-09-10 he408015781

    期待进一步的研究

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=36769, encodeId=f77936e69cd, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36770, encodeId=11b036e70c6, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36766, encodeId=110c36e6624, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36767, encodeId=4d4c36e6701, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36768, encodeId=dbc036e6858, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950091, encodeId=807e1950091bb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Mon Oct 27 19:28:00 CST 2014, time=2014-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275814, encodeId=82be12e5814bc, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341217, encodeId=37c6134121ec4, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364975, encodeId=c5ba13649e5f8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585947, encodeId=f1f7158594e2e, content=<a href='/topic/show?id=7ed041850a1' target=_blank style='color:#2F92EE;'>#基因组编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41850, encryptionId=7ed041850a1, topicName=基因组编辑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=)]
    2014-10-27 rebeccajiejie

    #RISPR/Cas9#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=36769, encodeId=f77936e69cd, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36770, encodeId=11b036e70c6, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36766, encodeId=110c36e6624, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36767, encodeId=4d4c36e6701, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36768, encodeId=dbc036e6858, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950091, encodeId=807e1950091bb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Mon Oct 27 19:28:00 CST 2014, time=2014-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275814, encodeId=82be12e5814bc, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341217, encodeId=37c6134121ec4, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364975, encodeId=c5ba13649e5f8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585947, encodeId=f1f7158594e2e, content=<a href='/topic/show?id=7ed041850a1' target=_blank style='color:#2F92EE;'>#基因组编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41850, encryptionId=7ed041850a1, topicName=基因组编辑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=)]
    2014-10-01 yuandd

    #CRISPR#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=36769, encodeId=f77936e69cd, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36770, encodeId=11b036e70c6, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36766, encodeId=110c36e6624, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36767, encodeId=4d4c36e6701, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36768, encodeId=dbc036e6858, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950091, encodeId=807e1950091bb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Mon Oct 27 19:28:00 CST 2014, time=2014-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275814, encodeId=82be12e5814bc, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341217, encodeId=37c6134121ec4, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364975, encodeId=c5ba13649e5f8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585947, encodeId=f1f7158594e2e, content=<a href='/topic/show?id=7ed041850a1' target=_blank style='color:#2F92EE;'>#基因组编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41850, encryptionId=7ed041850a1, topicName=基因组编辑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=)]
    2014-10-01 haouestc

    #CRISPR/Cas9#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=36769, encodeId=f77936e69cd, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36770, encodeId=11b036e70c6, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36766, encodeId=110c36e6624, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36767, encodeId=4d4c36e6701, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36768, encodeId=dbc036e6858, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950091, encodeId=807e1950091bb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Mon Oct 27 19:28:00 CST 2014, time=2014-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275814, encodeId=82be12e5814bc, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341217, encodeId=37c6134121ec4, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364975, encodeId=c5ba13649e5f8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585947, encodeId=f1f7158594e2e, content=<a href='/topic/show?id=7ed041850a1' target=_blank style='color:#2F92EE;'>#基因组编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41850, encryptionId=7ed041850a1, topicName=基因组编辑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=)]
    2014-10-01 respect

    #Cas9#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=36769, encodeId=f77936e69cd, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36770, encodeId=11b036e70c6, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:38:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36766, encodeId=110c36e6624, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36767, encodeId=4d4c36e6701, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36768, encodeId=dbc036e6858, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:37:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950091, encodeId=807e1950091bb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Mon Oct 27 19:28:00 CST 2014, time=2014-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275814, encodeId=82be12e5814bc, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341217, encodeId=37c6134121ec4, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364975, encodeId=c5ba13649e5f8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585947, encodeId=f1f7158594e2e, content=<a href='/topic/show?id=7ed041850a1' target=_blank style='color:#2F92EE;'>#基因组编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41850, encryptionId=7ed041850a1, topicName=基因组编辑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 01 00:28:00 CST 2014, time=2014-10-01, status=1, ipAttribution=)]
    2014-10-01 智智灵药

    #基因组编辑#

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

遗传性多发性骨软骨瘤发病机制的研究进展

遗传改变 HME是常染色体显性遗传病，约62％的患者有阳性家族史，目前已分离出2个相关基因：EXT1和EXT2，二者均为抑癌基因。欧美国家有研究发现，约90%的HME患者可检测出EXT1或EXT2基因突变，且EXT1突变与严重表型的相关性似乎大于EXT2及突变未检出者。 EXT1基因 EXT1基因含11个外显子，编码2238个位点。约44％~66％的HME患者可检测出EXT1致病突变。已

Science头条：为什么咖啡如此特别

由来自法国，美国、意大利、加拿大、中国等国家20多家研究机构的科学家们组成的一个研究小组对咖啡树进行了最新的测序，揭示出一些帮助生成咖啡因的酶在咖啡树、茶树和可可树（巧克力）中独立进化。 新测序的咖啡树基因组揭示出了有关人类最好的化学朋友：咖啡因进化的秘密。完成这一项目的科学家们说，咖啡树中一些基因的序列以及所在的位置表明，它们独立于茶树和可可树中具有相似功能、也生成咖啡因的一些基因进化

CSCO 2014 ：非小细胞肺癌基于药物靶基因的个体化化疗

非小细胞肺癌论坛—放化疗专场(1楼1F-1会议室)9月18日10:40~10:55         报告者:南京军区南京总医院 宋勇 肺癌是世界病死率最高的肿瘤,其中非小细胞肺癌(NSCLC)占80%以上,由于缺乏典型的早期症状,大多数患者在确诊时已经处于疾病的中晚期,从而失去手术机会,因此药物治疗成为肺癌的主

袁晶：使用CRISPR/Cas9介导的同源重组修复机制编辑疟原虫基因组

9月26日，由生物谷主办的2014基因组编辑研讨会在上海好望角大饭店隆重举行。厦门大学的袁晶教授参加了此次大会并发表了题为"Efficient Editing of Malaria Parasite Genome Using the CRIPR/Cas9 System"的精彩报告。 疟疾是由疟原虫属寄生虫感染引起的传染性疾病，全球每年约有数亿人口感染疟疾，其中上百人死亡。基于目前疟原虫对抗疟

CSCO 2014：青年医师论坛乳腺癌专场：多学科团队,全方位交流

两大特色,三种希望 青年医师论坛——乳腺癌">乳腺癌专场策划负责人、江苏省人民医院殷咏梅 一场论坛,两大特色 今年CSCO青年医师论坛的乳腺癌专场将会具有两大特色。首先是乳腺癌全程管理的理念,内容安排从术前新辅助治疗到乳腺癌前哨淋巴结相关问题,从辅助治疗到晚期解救治疗,均体现出了乳腺癌全程管理的理念。 各位讲者将分别就新辅助治疗策略和进展、辅助化疗和内分泌治疗进展、转移性乳腺癌化

Nature：人傻请不要怪基因！

Nature网站9月8日报道，寻找智力基因的科学家正举步维艰，针对人类认知所进行的最大、最严格的基因研究之一，其结果已变得无法确定。专家们承认，即使要令人信服地确认一个对智力及其它行为特征有影响的微小基因，也可能需要搜寻超过100万人的基因组。 过去人们对双胞胎的研究再次证明智力、个性及其它行为特征有其基因基础，但要把智商与DNA中的某个特定变异联系在一起，却带来了大量不可重

Baidu
map
Baidu
map
Baidu
map